Merck & Stock
Merck & Co., Inc.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- CEO
- Robert Davis
- Employees
- 74,000
- Market cap
- $360.1 B
- IPO
- 13/01/1978
Merck & Co., Inc. operates as a global player in the Drug Manufacturers - General industry, primarily active in the Pharmaceuticals and Animal Health segments. Its portfolio includes therapeutic solutions for oncology, immunology, and neuroscience, as well as essential preventative vaccines. In its animal health…
AI-generated company profile based on the figures on this page, last updated on 04/08/2026. Not investment advice.
Merck & stock: price history
1D
+0.5%
1W
+0.3%
1M
+0.7%
6M
+22.6%
YTD
+38.7%
1Y
+73.9%
2Y
+32.2%
5Y
+86.3%
10Y
+146.4%
Next earnings date
Next earnings date
29/10/2026 (in 12 days)
Volatility around earnings
~18% stronger price swings than usual
Merck & stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
1 more assignment (Enabler/Second row) Pro-only.
Merck & Co., Inc. is a global health care company operating through two business segments: Pharmaceuticals and Animal Health. The Pharma segment covers various therapeutic areas such as oncology and immunology, and develops vaccines for diverse age groups. In the Animal Health division, the company offers veterinary medicine as well as digital solutions for animal monitoring. The customer base includes pharmacies, hospitals, government agencies, as well as farmers and veterinarians in the animal health sector. Additionally, the company is active in strategic collaborations with other pharmaceutical companies.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Efficient scale
- Capital intensity
- High
- Customer concentration
- Unknown
Suppliers & customers in our universe
Agenus Inc.DescriptionAsk the agents about Merck &
Analyst assessment of Merck &
PRICE TARGET LOW
US$105.00
CONSENSUS
US$158.50
MEDIAN
US$165.50
PRICE TARGET HIGH
US$180.00
0
STRONG BUY
26
BUY
11
HOLD
1
SELL
0
STRONG SELL
38
TOTAL · Buy
As of: 12/10/2026
Merck & stock metrics
P/E
115.85
P/B
8.6
EV/EBITDA
29.24
RETURN ON EQUITY
-3.2%
NET MARGIN
-8.0%
DEBT/EQUITY
1.29
DIVIDEND YIELD
2.3%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.9%
FLOAT SHARES
2,464,616,479
AVG. DAILY VOLUME (30D)
9,647,766
Insider transactions (SEC)
Guindo Chirfi
Zachary Jennifer
Zachary Jennifer
Zachary Jennifer
DeLuca Richard R.
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: +0.5%
Search (Google Trends)
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Smart Money
Register for free
Register now to see which funds are invested
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Comparable stocks
Frequently asked questions about Merck & stock
What does Merck & do?
Merck & Co., Inc. is a company in the Healthcare sector, Drug Manufacturers - General industry, headquartered in United States.
The CEO is Robert Davis, the company employs around 74,000 people.
The IPO was on 13/01/1978; the stock trades on NYSE under the ticker MRK.
What do analysts say about Merck & stock?
38 analysts rate the stock, the consensus is Buy (as of 12/10/2026).
The average price target is US$158.50, ranging from US$105.00 to US$180.00, with a median of US$165.50.
This is an external assessment, not a statement by Market Jury.
When does Merck & report next?
The next earnings date is 29/10/2026.
Around past earnings, price swings were roughly 18% stronger than usual.
Does Merck & pay a dividend?
Yes. The last dividend was US$0.85 per share, ex-date 15/09/2026, paid on 07/10/2026.
The dividend yield is 2.3% (as of 30/06/2026).
Which stocks are comparable to Merck &?
Comparable stocks include Eli Lilly and Company, Johnson & Johnson, AbbVie, Amgen, Gilead Sciences, Pfizer, Bristol-Myers Squibb Company and Biogen.
How can I get Merck & stock analyzed?
Clicking "Analyze stock" lets five strategies assess Merck & against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.